黄芪注射液对慢性阻塞性肺病病人血清负急性期蛋白的影响

Therapeutic Effect of Huanqi Injection on Negative Acute Phase Protein in Chronic Obstructive Pulmonary Disease

应用黄芪注射液治疗 36例慢性阻塞性肺病 (COPD)病人 ,观察其对血清负急性期蛋白的影响。在常规治疗的基础上 ,静脉滴注黄芪注射液 2周 ,测定治疗前后血清白蛋白 (AIb)、前白蛋白 (PA)、转铁蛋白 (Tf) ,观察临床疗效 ,并与常规治疗对照组比较分析。结果显示黄芪治疗组临床改善优于对照组 (P<0 .0 5 ) ,治疗后 AIb、PA、Tf显著升高 ,而对照组变化不明显 (P>0 .0 5 )。表明黄芪注射液可增加 COPD病人血清负急性期蛋白的浓度 ,提高治疗效果。

To observe the clinical therapeutic effect of Huangqi Injection(HQI) on negative acute phase protein in chronic obstructive pulmonary disease(COPD). 36 patients with COPD were continously treated with HQI by intravenous drip for 14 days and the serum albumin (AIb), prealbumin(PA), transfer ferric protein (Tf), and clinical effect were examined both before and after treatment and compared with itself or control group. The result showed that post therapeutically , the clinical effect of the treatment group was better than that of the control group(P<0.05),and that the testing parameters was greatly increased in the treatment group(P<0.01),while there was difference found in the control group (P>0.05).All these findings led to a conclusion that HQI, by increasing negative acute phase protein in COPD, could improve the therapeutic effect in cases of COPD.